191 related articles for article (PubMed ID: 1979431)
1. Decreased tyrosine hydroxylase messenger RNA in the surviving dopamine neurons of the substantia nigra in Parkinson's disease: an in situ hybridization study.
Javoy-Agid F; Hirsch EC; Dumas S; Duyckaerts C; Mallet J; Agid Y
Neuroscience; 1990; 38(1):245-53. PubMed ID: 1979431
[TBL] [Abstract][Full Text] [Related]
2. Immunocytochemical quantification of tyrosine hydroxylase at a cellular level in the mesencephalon of control subjects and patients with Parkinson's and Alzheimer's disease.
Kastner A; Hirsch EC; Herrero MT; Javoy-Agid F; Agid Y
J Neurochem; 1993 Sep; 61(3):1024-34. PubMed ID: 8103078
[TBL] [Abstract][Full Text] [Related]
3. Tyrosine hydroxylase protein and messenger RNA in the dopaminergic nigral neurons of patients with Parkinson's disease.
Kastner A; Hirsch EC; Agid Y; Javoy-Agid F
Brain Res; 1993 Mar; 606(2):341-5. PubMed ID: 8098254
[TBL] [Abstract][Full Text] [Related]
4. Acute and repeated administration of fluphenazine-N-mustard alters levels of tyrosine hydroxylase mRNA in subsets of mesencephalic dopaminergic neurons.
Weiss-Wunder LT; Chesselet MF
Neuroscience; 1992 Jul; 49(2):297-305. PubMed ID: 1359452
[TBL] [Abstract][Full Text] [Related]
5. Differential modification of dopamine transporter and tyrosine hydroxylase mRNAs in midbrain of subjects with Parkinson's, Alzheimer's with parkinsonism, and Alzheimer's disease.
Joyce JN; Smutzer G; Whitty CJ; Myers A; Bannon MJ
Mov Disord; 1997 Nov; 12(6):885-97. PubMed ID: 9399211
[TBL] [Abstract][Full Text] [Related]
6. ALDH1 mRNA: presence in human dopamine neurons and decreases in substantia nigra in Parkinson's disease and in the ventral tegmental area in schizophrenia.
Galter D; Buervenich S; Carmine A; Anvret M; Olson L
Neurobiol Dis; 2003 Dec; 14(3):637-47. PubMed ID: 14678778
[TBL] [Abstract][Full Text] [Related]
7. trkB messenger RNA expression in normal human brain and in the substantia nigra of parkinsonian patients: an in situ hybridization study.
Benisty S; Boissiere F; Faucheux B; Agid Y; Hirsch EC
Neuroscience; 1998 Oct; 86(3):813-26. PubMed ID: 9692719
[TBL] [Abstract][Full Text] [Related]
8. Disease duration and the integrity of the nigrostriatal system in Parkinson's disease.
Kordower JH; Olanow CW; Dodiya HB; Chu Y; Beach TG; Adler CH; Halliday GM; Bartus RT
Brain; 2013 Aug; 136(Pt 8):2419-31. PubMed ID: 23884810
[TBL] [Abstract][Full Text] [Related]
9. Regional distribution of monoamine vesicular uptake sites in the mesencephalon of control subjects and patients with Parkinson's disease: a postmortem study using tritiated tetrabenazine.
Thibaut F; Faucheux BA; Marquez J; Villares J; Menard JF; Agid Y; Hirsch EC
Brain Res; 1995 Sep; 692(1-2):233-43. PubMed ID: 8548309
[TBL] [Abstract][Full Text] [Related]
10. Lesions of nigrostriatal pathway reduce expression of tyrosine hydroxylase gene in residual dopaminergic neurons of substantia nigra.
Shirao T; Evinger MJ; Iacovitti L; Reis DJ
Neurosci Lett; 1992 Jul; 141(2):208-12. PubMed ID: 1359468
[TBL] [Abstract][Full Text] [Related]
11. The vulnerability of nigral neurons to Parkinson's disease is unrelated to their intrinsic capacity for dopamine synthesis: an in situ hybridization study.
Kingsbury AE; Marsden CD; Foster OJ
Mov Disord; 1999 Mar; 14(2):206-18. PubMed ID: 10091611
[TBL] [Abstract][Full Text] [Related]
12. Chronic lesions differentially decrease tyrosine hydroxylase messenger RNA in dopaminergic neurons of the substantia nigra.
Pasinetti GM; Lerner SP; Johnson SA; Morgan DG; Telford NA; Finch CE
Brain Res Mol Brain Res; 1989 May; 5(3):203-9. PubMed ID: 2566883
[TBL] [Abstract][Full Text] [Related]
13. Is Bax a mitochondrial mediator in apoptotic death of dopaminergic neurons in Parkinson's disease?
Hartmann A; Michel PP; Troadec JD; Mouatt-Prigent A; Faucheux BA; Ruberg M; Agid Y; Hirsch EC
J Neurochem; 2001 Mar; 76(6):1785-93. PubMed ID: 11259496
[TBL] [Abstract][Full Text] [Related]
14. Subpopulations of mesencephalic dopaminergic neurons express different levels of tyrosine hydroxylase messenger RNA.
Weiss-Wunder LT; Chesselet MF
J Comp Neurol; 1991 Jan; 303(3):478-88. PubMed ID: 1672536
[TBL] [Abstract][Full Text] [Related]
15. Heterogeneity of melanized neurons expressing neurotensin receptor messenger RNA in the substantia nigra and the nucleus paranigralis of control and Parkinson's disease brain.
Yamada M; Yamada M; Richelson E
Neuroscience; 1995 Jan; 64(2):405-17. PubMed ID: 7700529
[TBL] [Abstract][Full Text] [Related]
16. Tyrosine hydroxylase mRNA in the dopaminergic neurons of young adult and aged mice by in situ hybridization.
Gupta M; Stoler MH; Fossom LH; Tank AW
Neurosci Lett; 1990 Oct; 119(1):49-52. PubMed ID: 1982959
[TBL] [Abstract][Full Text] [Related]
17. Decreased tyrosine hydroxylase content in the dopaminergic neurons of MPTP-intoxicated monkeys: effect of levodopa and GM1 ganglioside therapy.
Kastner A; Herrero MT; Hirsch EC; Guillen J; Luquin MR; Javoy-Agid F; Obeso JA; Agid Y
Ann Neurol; 1994 Aug; 36(2):206-14. PubMed ID: 7914399
[TBL] [Abstract][Full Text] [Related]
18. Effect of siRNA-induced silencing of cellular prion protein on tyrosine hydroxylase expression in the substantia nigra of a rat model of Parkinson's disease.
Wang X; Yang HA; Wang XN; Du YF
Genet Mol Res; 2016 May; 15(2):. PubMed ID: 27173342
[TBL] [Abstract][Full Text] [Related]
19. Loss of non-phosphorylated neurofilament immunoreactivity, with preservation of tyrosine hydroxylase, in surviving substantia nigra neurons in Parkinson's disease.
Gai WP; Vickers JC; Blumbergs PC; Blessing WW
J Neurol Neurosurg Psychiatry; 1994 Sep; 57(9):1039-46. PubMed ID: 7916375
[TBL] [Abstract][Full Text] [Related]
20. Reduced BDNF mRNA expression in the Parkinson's disease substantia nigra.
Howells DW; Porritt MJ; Wong JY; Batchelor PE; Kalnins R; Hughes AJ; Donnan GA
Exp Neurol; 2000 Nov; 166(1):127-35. PubMed ID: 11031089
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
